Stahl Online is a one-stop shop, covering everything a mental health professional or teacher will ever need to know about neuropsychopharmacology. Comprehensive and regularly updated, Stahl Online provides full access to the entire current portfolio of books by Dr Stephen M. Stahl.
Stahl Online is a one-stop shop, covering everything a mental health professional or teacher will ever need to know about neuropsychopharmacology. Comprehensive and regularly updated, Stahl Online provides full access to the entire current portfolio of books by Dr Stephen M. Stahl.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Edited by
Katherine Warburton, California Department of State Hospitals, University of California, Davis, USA,Stephen M. Stahl, University of California, Riverside, USA
This chapter explores the ethical, legal, and clinical dimensions of treatment without consent in psychiatry, particularly in the context of neuroethics. Drawing on principles from the European Convention on Human Rights (ECHR), the authors argue for a goal-oriented, process-based approach to ethical decision-making that prioritizes restoring mental capacity, dignity, and autonomy. The chapter critiques the limitations of functional mental capacity assessments and advocates for a layered understanding of consciousness grounded in neuroscience. It emphasizes the ethical duty to intervene when necessary, especially in cases involving neurodegenerative psychotic disorders (NDPPD), and highlights the importance of early, potentially disease-modifying interventions. The authors call for inclusive research practices, structured clinical decision-making, and a compassionate, scientifically grounded framework that transcends simplistic dichotomies of paternalism and liberty.
Edited by
Katherine Warburton, California Department of State Hospitals, University of California, Davis, USA,Stephen M. Stahl, University of California, Riverside, USA
Edited by
Katherine Warburton, California Department of State Hospitals, University of California, Davis, USA,Stephen M. Stahl, University of California, Riverside, USA
Balancing autonomy and beneficence remains an ongoing challenge in the ethical treatment of patients with schizophrenia and other psychiatric disorders of thought. Psychiatric advance directives (PADs) offer one mechanism through which individuals can guide their own care, but unlike medical advance directives, they are not widely utilized in the United States. They are also highly limited by state law in the scope of their legal authority. This article explores the evidentiary basis for PADs as well as the legal and ethical issues that arise in the use of PADsin individuals with schizophrenia, arguing that providers’ fears of complete opt-out from care by patients are likely unfounded and that PADs offer a powerful tool through which individuals with schizophrenia can ensure meaningful consideration of their own values and goals.
Edited by
Katherine Warburton, California Department of State Hospitals, University of California, Davis, USA,Stephen M. Stahl, University of California, Riverside, USA
Anosognosia, commonly understood as a lack of insight, renders individuals with schizophreniaand schizoaffective disorder unable to understand that they are living with a disease, often resulting in a refusal to accept treatment. Typically, to impose involuntary commitment in an effort to obtain treatment, an individualmust be a danger to others or themselves. Even if involuntary commitment is imposed, however, an individualmay remain competent to refuse medication—despite symptoms of anosognosia and an inability to understand that they are ill. This article examines the existing legal theories of competency and informed consent and proposes a statutory definition of competency that encompasses the specific needs of people with anosognosia, while considering the significant interests at stake when taking away an individual’s right to choose or refuse treatment.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of substance use disorders and impulsive-compulsive disorders, including neurobiology of impulsivity and compulsivity, neurobiology of reward, mechanisms of drugs of abuse, treatments for substance use disorders, and treatments for impulsive-compulsive disorders such as obsessive compulsive disorder (OCD).
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of unipolar depression, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of bipolar disorder, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of sleep/wake disorders, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of anxiety and stress-related disorders, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of dementia, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of attention deficit hyperactivity disorder, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of neuropathic pain, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of basic neuroscience, including synaptic neurotransmission, chemical neurotransmission, receptors, ion channels, enzymes, and the relationship between genes, environment, and behavior.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of psychosis and schizophrenia, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
This unique book offers a methodical exploration of biological, social, and ethical topics on the treatment (or lack thereof) of psychotic brain disease. Part I provides an empirical engagement with neuroscience and covers the neurobiology and pharmacology of schizophrenia, providing the reader with a current understanding of the disease. Topic areas include anosognosia, community treatments, and early intervention. Part II looks at international policy approaches to schizophrenia featuring topics such as the policy, funding, and historical elements contributing to frequently misguided approaches to severe brain disease, and it explains why some societies won't/can't support human beings with psychotic disease. Part III focuses on neuroethics and asks: 'What is right?' through chapters discussing the concepts of consciousness and free will, as well as the principles of nonmaleficence, beneficence, autonomy, and justice. Collectively the comprehensive approach of this book allows the reader to gain a full understanding of the ethical and clinical complexities in treating schizophrenia.
This fully updated fifth edition offers over 150 case-based multiple-choice questions across ten core areas of psychiatry and psychopharmacology. An essential learning resource for psychiatrists, primary care physicians, nurse practitioners, psychologists, and pharmacists, it helps identify knowledge gaps and guide further study. Each question includes detailed explanations and references, enabling users to diagnose psychiatric symptoms, implement evidence-based treatments, and integrate recent advances into clinical practice. Aligned with Stahl's Essential Psychopharmacology, the content spans neurobiology to psychopharmacologic strategies and reflects current best practices and clinical dilemmas. Cross-references to key Stahl titles enhance integrated study, while peer benchmarking allows users to assess their proficiency. Ideal for trainees and experienced professionals alike, this book transforms exam preparation into a deeper, clinically relevant learning experience.
